Showing results (471-480 of 583) with videos related to
Sort By:
Pageof 59
Journal of Medicinal Chemistry|August 5, 2008
Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivityRalf Heim, Simon Lucas, Cornelia M Grombein, et al.Leukemia Research|January 1, 1986
Human leukemic cells: receptor binding and biological effects of insulin and insulin-like growth factorsU Vetter, J H Schlickenrieder, J Zapf, et al.Neuro-Ophthalmology (Aeolus Press)|July 18, 2019
Papilloedema from Dural Venous Sinus Compression by MeningiomasAlexander J P W Hartmann, Michelle W Latting, Michael S Lee, et al.Health Services Research|July 22, 2009
Comparing safety climate between two populations of hospitals in the United StatesSara J Singer, Christine W Hartmann, Amresh Hanchate, et al.Journal of Medicinal Chemistry|August 8, 2013
Discovery and biophysical characterization of 2-amino-oxadiazoles as novel antagonists of PqsR, an important regulator of Pseudomonas aeruginosa virulenceMichael Zender, Tobias Klein, Claudia Henn, et al.Disease Management : DM|March 24, 2004
Impact of appropriate pharmaceutical therapy for chronic conditions on direct medical costs and workplace productivity: a review of the literatureNeil Goldfarb, Christine Weston, Christine W Hartmann, et al.Journal of Medicinal Chemistry|May 30, 2003
Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapyOmoshile O Clement, Clive M Freeman, Rolf W Hartmann, et al.Chemmedchem|January 28, 2021
Phosphonate as a Stable Zinc-Binding Group for "Pathoblocker" Inhibitors of Clostridial Collagenase H (ColH)Katrin Voos, Esther Schönauer, Alaa Alhayek, et al.Plos One|February 4, 2014
A novel malaria vaccine candidate antigen expressed in Tetrahymena thermophilaGraeme J M Cowan, Ulrike Bockau, Janna Eleni-Muus, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2002
A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patientsJ Jassem, R Ramlau, H Karnicka-Młodkowska, et al.Pageof 59